Nothing Special   »   [go: up one dir, main page]

WO2001081361A8 - Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death - Google Patents

Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death

Info

Publication number
WO2001081361A8
WO2001081361A8 PCT/US2001/011501 US0111501W WO0181361A8 WO 2001081361 A8 WO2001081361 A8 WO 2001081361A8 US 0111501 W US0111501 W US 0111501W WO 0181361 A8 WO0181361 A8 WO 0181361A8
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
disorders
compositions
diseases involving
cell
Prior art date
Application number
PCT/US2001/011501
Other languages
French (fr)
Other versions
WO2001081361B1 (en
WO2001081361A1 (en
Inventor
Stuart D Portbury
Kasturi Puranam
Lawrence C Katz
Donald C Lo
Shawn Barney
Mary Beth Thomas
Original Assignee
Cogent Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cogent Neuroscience Inc filed Critical Cogent Neuroscience Inc
Priority to AU2001256998A priority Critical patent/AU2001256998A1/en
Publication of WO2001081361A1 publication Critical patent/WO2001081361A1/en
Publication of WO2001081361A8 publication Critical patent/WO2001081361A8/en
Publication of WO2001081361B1 publication Critical patent/WO2001081361B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death, including, but not limited to, neurological disorders such as stroke. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced.
PCT/US2001/011501 2000-04-11 2001-04-09 Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death WO2001081361A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256998A AU2001256998A1 (en) 2000-04-11 2001-04-09 Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54793800A 2000-04-11 2000-04-11
US09/547,938 2000-04-11

Publications (3)

Publication Number Publication Date
WO2001081361A1 WO2001081361A1 (en) 2001-11-01
WO2001081361A8 true WO2001081361A8 (en) 2002-02-28
WO2001081361B1 WO2001081361B1 (en) 2002-06-27

Family

ID=24186756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011501 WO2001081361A1 (en) 2000-04-11 2001-04-09 Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death

Country Status (2)

Country Link
AU (1) AU2001256998A1 (en)
WO (1) WO2001081361A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097687A2 (en) * 2002-05-16 2003-11-27 Ikuo Nishimoto Neuroprotective polypeptides and methods of use
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
AU2008297888A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8637470B2 (en) 2008-05-01 2014-01-28 The Regents Of The University Of California Small humanin-like peptides
WO2021030749A1 (en) * 2019-08-15 2021-02-18 Cohbar, Inc. Therapeutic peptides
US20220306691A1 (en) * 2019-08-15 2022-09-29 Cohbar, Inc. Therapeutic peptides
US20220305079A1 (en) * 2019-08-15 2022-09-29 Cohbar, Inc. Therapeutic peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product

Also Published As

Publication number Publication date
AU2001256998A1 (en) 2001-11-07
WO2001081361B1 (en) 2002-06-27
WO2001081361A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
WO2004013155A3 (en) Stabilisation of nucleic acids
WO1997022619A3 (en) INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO2004014222A3 (en) Diagnosis and treatment of tuberous sclerosis
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
EP2264069A3 (en) Purification of fibrinogen
CA2459351A1 (en) Methods for treating deodorizer distillate
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1163515A4 (en) DIAGNOSTIC AND THERAPEUTIC TOOLS FOR TREATING NUCLEAR TOLERANCE DISORDERS
WO2001081361A8 (en) Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death
BR9906926A (en) Compositions and methods for treating cells having double minute dna
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO1999025829A3 (en) Cdk2 protein and cdk2 protein complexes
WO2002000691A3 (en) Polynucleotides and polypeptides encoded thereby
GB9610281D0 (en) Diagnostic method and apparatus
WO2024023262A3 (en) Nucleic acid compounds
WO2001096873A3 (en) Method for identifying apoptosis-modified proteins
EP1363528A4 (en) Methods for diagnosing and treating heart disease
WO2002099064A3 (en) Rna purification methods
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003054541A3 (en) Inhibition of tristetraproline for protection of the heart from cardiac injuries

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED:03.02.03)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP